Peter Stoddard's questions to Biostem Technologies Inc (BSEM) leadership • Q2 2024
Question
Peter Stoddard of Stoddard Investments referenced the comments on the proposed 2025 CMS physician fee schedule and asked how this impacts BioStem and positions the company for changes in LCDs.
Answer
Executive Jason Matuszewski clarified that since CMS did not propose changes to the ASP pricing methodology for skin substitutes in the physician office setting, there is no immediate pricing risk there. However, he acknowledged that proposed LCDs could still lead to market disruption. He asserted that BioStem is well-positioned to navigate these changes because its clinical trial initiatives are designed to generate the evidence required to meet proposed Medicare coverage requirements.